AGIO News and Press, Agios Pharmaceuticals Inc. From 12/26/25

2025-12-26 07:05:46 ET from Leerink Partners issued a price target of $40.00 for AGIO on 2025-12-26 11:26:49. The adjusted price target was set to $40.00. At the time of the announcement, AGIO was trading at $29.17. The overall price target consensus is at $39.75 with hi...

2025-12-24 16:56:09 ET Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia December 24, 2025 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Agios Pharmaceuticals, Inc. (AGIO) Discusses ...

2025-12-24 13:05:50 ET from H.C. Wainwright issued a price target of $62.00 for AGIO on 2025-12-24 17:29:10. The adjusted price target was set to $62.00. At the time of the announcement, AGIO was trading at $29.17. The overall price target consensus is at $36.75 with hig...

2025-12-24 12:48:08 ET It has been nearly one year since I last covered Agios Pharma (NASDAQ: AGIO ), rating the company a hold. Since the stock has returned -29%, lagging the market by 47%, justifying my cautious stance. However, yesterday on December 23rd, the stock was halted...

2025-12-24 12:23:24 ET Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME (mitapivat) for the treatment of anemia in both non-transfu...

2025-12-23 23:34:01 ET More on Agios Pharmaceuticals Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript ...

AQVESME is the only FDA-approved medicine for anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia Marketed under AQVESME brand name in the U.S. for thalassemia indication; PYRUKYND® (mitapivat) remains the U.S. brand name for PK deficiency indicati...

CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has not yet iss...

2025-11-20 11:16:54 ET More on Agios Pharmaceuticals Agios Pharma: Study Fail May Affect Mitapivat TDT Approval - Expect More Volatility Agios Pharmaceuticals, Inc. (AGIO) Discusses Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease Transcript ...

A look at the top 10 most actives in the United States Autozi Internet Technology (Global) Ltd. (AZI) rose 12.0% to $0.085 on volume of 480,945,530 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 5.1% to $4.13 on volume of 355,767,751 shares Freight Technologies Inc. (FRGT) r...